Author:
Upshaw Jenica N.,Nelson Jason,Sweigart Benjamin,Rodday Angie Mae,Kumar Anita J.,Konstam Marvin A.,Wong John B.,Ky Bonnie,Karmiy Samuel,Friedberg Jonathan W.,Evens Andrew M.,Kent David M.,Parsons Susan K.
Funder
National Institutes of Health
Reference39 articles.
1. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk;van Nimwegen;JAMA Intern Med,2015
2. Development and validation of risk prediction models for coronary heart disease and heart failure after treatment for Hodgkin lymphoma;de Vries;J Clin Oncol,2023
3. Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000-2016;Dores;J Clin Oncol,2020
4. Surveillance, Epidemiology, and End Results. Cancer statistics,2022
5. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma;Evens;J Clin Oncol,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献